Assessing the Role of Radiotherapy in Patients with Refractory or Relapsed High-Grade B-Cell Lymphomas Treated with CAR T-Cell Therapy
Non-Hodgkin lymphoma (NHL) is the most prevalent hematologic malignancy1, accounting for approximately 4.3% of all new cancers and 3.4% of all cancer deaths in the United States2. Diffuse large B-cell lymphoma (DLBCL) constitutes 30-40% of all NHL cases in the U.S.3. In the last few decades, the survival rates have improved to a 5-year relative survival rate of 63.9% in the United States and 55.4% in Europe4,5. The most common upfront treatment for patients with DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with select patients receiving consolidative radiation therapy (RT) following R-CHOP, particularly with limited-stage, bulky disease6,7.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Hazim S. Ababneh, Jeremy S. Abramson, P. Connor Johnson, Chirayu G. Patel Tags: Review Article Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Radiation Therapy | Radiology | Rituxan | USA Health